文献速递妇科生殖医学

子宫内膜异位症微创术后再手术率:22,644例患者表型特异性荟萃分析

Reoperation After Minimally Invasive Endometriosis Surgery: A Phenotype-Specific Meta-analysis of 22,644 Patients.
PubMed 文献 · J Minim Invasive Gynecol · 2026-07-24

亚组分析显示结直肠和泌尿道内异症再手术率较低,术后药物治疗者再手术率低于未治疗者(4.40% vs 11.23%)。

要点

  • 微创内异症手术后约十分之一患者需再手术,总体再手术率10.81%。
  • 结直肠和泌尿道内异症再手术率低于混合型和腹膜型。
  • 术后药物治疗与再手术率降低相关,子宫切除显示非显著降低趋势。

核心结论

  • 约十分之一的患者在接受子宫内膜异位症微创手术后需要再手术。
  • 再手术率因疾病表型、手术策略、术后抑制治疗和随访时间而异。
  • 强调需要针对表型进行咨询并标准化报告长期手术结局。

研究设计与样本

  • 系统综述与荟萃分析,遵循PRISMA和Cochrane指南。
  • 检索PubMed、Embase和CENTRAL从建库至2026年5月。
  • 采用随机效应广义线性混合模型估计合并事件率,使用RoB 2和ROBINS-I评估偏倚风险,GRADE评估证据确定性。

主要发现

  • 合并再手术率为10.81%(95% CI 8.10至14.0;I2=95.7%)。
  • 结直肠内异症再手术率为5.14%,泌尿道内异症为3.98%,均低于混合型和腹膜型疾病,但异质性较大。
  • 在报告术后激素管理的>研究中,接受术后药物治疗者再手术率为4.40%,未治疗者为11.23%。
  • 子宫切除与后续再手术风险降低呈非显著趋势(HR 0.48;95% CI 0.22至1.08)。

关键数值与推荐

  • 总体再手术率10.81%(95% CI 8.10至14.0)。
  • 结直肠内异症再手术率5.14%。
  • 泌尿道内异症再手术率3.98%。
  • 术后药物治疗者再手术率4.40%,未治疗者11.23%。
  • 子宫切除与再手术风险HR 0.48(95% CI 0.22至1.08)。

临床怎么用

  • 术前咨询应告知患者微创内异症手术后约10%的再手术风险。
  • 根据内异症表型(如结直肠、泌尿道)提供特异性再手术风险咨询。
  • 术后考虑激素抑制治疗以可能降低再手术风险。
  • 子宫切除对再手术风险的影响需个体化评估,现有证据未达统计学显著性。

局限性

  • 研究间异质性显著(I2=95.7%)。
  • 亚组分析中异质性仍较大。
  • 子宫切除与再手术风险的关联未达统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the incidence of reoperation after minimally invasive surgery for endometriosis and to explore differences according to disease subtype, surgical technique, hysterectomy, postoperative hormonal therapy, and follow-up duration. DATA SOURCES: We conducted a systematic review and meta-analysis according to PRISMA and Cochrane guidance. PubMed, Embase, and CENTRAL were searched from inception to May 2026. METHODS OF STUDY SELECTION: Eligible studies enrolled women with surgically confirmed endometriosis treated by minimally invasive surgery and reported reoperation after the index procedure. Pooled event rates were estimated using random-effects generalized linear mixed models. Risk of bias was assessed with RoB 2 and ROBINS-I, and certainty of evidence was evaluated with GRADE. The primary outcome was the reoperation rate after minimally invasive surgery for endometriosis. Subgroup analyses were conducted according to surgical technique and endometriosis subtype. We also evaluated reoperation rates according to postoperative hormonal treatment use after the index surgery and the risk of subsequent hysterectomy following endometriosis surgery. TABULATION, INTEGRATION, AND RESULTS: Fifty-seven studies including 22,644 patients were included. The pooled reoperation rate was 10.81% (95% CI 8.10 to 14.0; I2=95.7%). In subgroup analyses, reoperation rates were lower in colorectal endometriosis (5.14%), and urinary tract endometriosis (3.98%) than in mixed disease and peritoneal disease, although heterogeneity was substantial. Among studies reporting postoperative hormonal management, reoperation was lower in patients receiving postoperative medical treatment than in those without treatment (4.40% vs 11.23%). Hysterectomy showed a nonsignificant trend toward lower subsequent reoperation risk (HR 0.48; 95% CI, 0.22 to 1.08). CONCLUSION: Approximately one in ten patients underwent reoperation after minimally invasive surgery for endometriosis. Reported reoperation rates varied according to disease phenotype, surgical strategy, postoperative suppression, and follow-up duration, underscoring the need for phenotype-specific counseling and standardized reporting of long-term surgical outcomes.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Lemos MJ, Servidoni ACP, de Mattos ILL, et al. Reoperation After Minimally Invasive Endometriosis Surgery: A Phenotype-Specific Meta-analysis of 22,644 Patients. J Minim Invasive Gynecol. 2026. PMID: 42498214. doi:10.1016/j.jmig.2026.07.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。